# Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT07483385** · NA · RECRUITING · sponsor: **The General Hospital of Western Theater Command** · enrollment: 45 (estimated)

## Conditions studied

- Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
- Hematologic Disorders

## Interventions

- **DRUG:** Lusutrombopag

## Key facts

- **NCT ID:** NCT07483385
- **Lead sponsor:** The General Hospital of Western Theater Command
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-13
- **Primary completion:** 2027-01-28
- **Final completion:** 2028-01-28
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483385, "Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07483385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*